Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits
Key facts
- Who runs it
- Shandong Provincial Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,324 people, planned
- Started
- 15 Oct 2026
- Expected to end
- Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tenecteplase 0.18 mg/kg
- Tenecteplase 0.25 mg/kg
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Age ≥18 years
- Clinical diagnosis of acute ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) score ≤5
- Presence of clearly disabling neurological deficits that persist and prevent the participant from independently performing at least one basic activity of daily living (including bathing, dressing, walking, toileting, personal hygiene, and eating) and/or returning to their previous work
- Time from stroke onset to treatment <4.5 hours, with onset defined as the time of symptom onset or the last known well time
- Pre-stroke modified Rankin Scale (mRS) score ≤1
- Voluntary participation and written informed consent provided by the participant or their legally authorized representative
Who cannot take part
- Recent anticoagulant treatment with coagulation parameters that do not meet the safety requirements for thrombolysis
- Concomitant bacterial endocarditis, pericarditis, acute pancreatitis, or other severe, difficult-to-control infections
- Current participation in another interventional medical device or drug study, or completion of participation in such a study less than 30 days previously
- Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma
- History of intracranial hemorrhage, or presence of an intra-axial intracranial tumor, giant intracranial aneurysm, or arteriovenous malformation
- History of stroke within the preceding 3 months
- History of major trauma (e.g., severe head injury within the preceding 3 months), surgery or invasive procedures (e.g., intracranial or spinal canal surgery within the preceding 3 months, major surgery within the preceding 2 weeks, or arterial puncture at a site not amenable to compression within the preceding week), or bleeding (e.g., gastrointestinal or urinary tract bleeding within the preceding 3 weeks)
- Persistent uncontrolled hypertension despite active antihypertensive treatment: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg
- Postictal paresis (Todd's paresis), or other neurological or psychiatric conditions resulting in inability or unwillingness to cooperate
- Known allergy to the active ingredient rhTNK-tPA or any of its excipients
- Other serious diseases associated with a life expectancy of less than 6 months
- Any other condition that, in the investigator's judgment, may substantially increase bleeding risk, interfere with study assessments, or render the participant unsuitable for the trial
- Active internal bleeding or an acute bleeding tendency, including a platelet count <100 × 10⁹/L
- Blood glucose <2.8 mmol/L or >22.22 mmol/L. Eligibility may be reassessed after correction of blood glucose if clearly disabling neurological deficits associated with minor stroke persist and the participant meets the diagnostic criteria for acute ischemic stroke and the eligibility requirements for intravenous thrombolysis
- NIHSS item 1a score >2
- Planned endovascular treatment before randomization
- Pregnancy, breastfeeding, or unwillingness of a female participant to use effective contraception during the trial
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Acute ischemic stroke or minor ischemic stroke
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work.
Read full original descriptionShow less
The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses.
Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not.
Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.
The 2 groups in the trial
- Low-Dose Tenecteplase (rhTNK-tPA)Treatment being tested
Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Treatment: Tenecteplase 0.18 mg/kg
- Standard-Dose Tenecteplase (rhTNK-tPA)Existing treatment, for comparison
Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Treatment: Tenecteplase 0.25 mg/kg
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Low-Dose Recombinant Human Tenecteplase Tissue-Type Plasminogen Activator for Injection in Acute Minor Ischemic Stroke With Disabling Deficits: The MILD-EFFECT Multicenter Randomized Controlled Trial
- Criteria questions
- Built from NCT07944261, who can take part
- Record updated
- 18 November 2026